Invention Grant
- Patent Title: Anti-human CEACAM5 antibody Fab fragment
-
Application No.: US16628975Application Date: 2018-07-06
-
Publication No.: US11667724B2Publication Date: 2023-06-06
- Inventor: Hitoshi Doihara , Kazunori Hirayama , Hiroki Shirai
- Applicant: ASTELLAS PHARMA INC.
- Applicant Address: JP Tokyo
- Assignee: ASTELLAS PHARMA INC.
- Current Assignee: ASTELLAS PHARMA INC.
- Current Assignee Address: JP Tokyo
- Agency: Marshall, Gerstein & Borun LLP
- Priority: JP 2017133698 2017.07.07
- International Application: PCT/JP2018/025618 2018.07.06
- International Announcement: WO2019/009388A 2019.01.10
- Date entered country: 2020-01-06
- Main IPC: A61K51/10
- IPC: A61K51/10 ; C07K16/30 ; G01N33/574

Abstract:
Provided are an anti-human CEACAM5 antibody Fab fragment expected to be useful in the diagnosis of a cancer, particularly, the diagnosis of colorectal cancer, breast cancer, lung cancer, thyroid gland cancer or a cancer resulting from the metastasis thereof, and a diagnosis approach using a conjugate comprising the Fab fragment. The present invention provides an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 121 of SEQ ID NO: 2, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by amino acid positions 1 to 112 of SEQ ID NO: 4, and a conjugate comprising the Fab fragment.
Information query